Atlas Trials

Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence

Clinical trial NCT04213118 · UNKNOWN

Trial details

NCT number
NCT04213118
Sponsor
First Affiliated Hospital Xi'an Jiaotong University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Hepatocellular CarcinomaTACEAnlotinib
Start date
2020-04-23
Primary completion
2023-02-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.